The discrepancy between the mOS in our study for CPS B patients and the results reported in the SHARP trial is explained by the fact that the vast majority of patients included in the SHARP study had well-compensated liver cirrhosis (CPS A). The gene discussed is OPN1SW; the disease is cirrhosis of liver.